{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T09:33:07Z","timestamp":1751275987752,"version":"3.38.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00520-025-09258-3","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T03:57:19Z","timestamp":1739851039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Approaches to management of endocrine therapy\u2013induced alopecia in breast cancer patients"],"prefix":"10.1007","volume":"33","author":[{"given":"Michelle","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawna","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"9258_CR1","doi-asserted-by":"publisher","unstructured":"Siegel, RL, Giaquinto, AN, & Jemal, A (2024) Cancer statistics, 2024.\u00a0CA: a cancer journal for clinicians 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","DOI":"10.3322\/caac.21820"},{"key":"9258_CR2","doi-asserted-by":"publisher","first-page":"e1918160","DOI":"10.1001\/jamanetworkopen.2019.18160","volume":"3","author":"Y Li","year":"2020","unstructured":"Li Y, Yang D, Yin X et al (2020) Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone receptor-positive breast cancer. JAMA Netw Open 3:e1918160. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18160","journal-title":"JAMA Netw Open"},{"key":"9258_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10549-007-9548-1","volume":"107","author":"D Cella","year":"2008","unstructured":"Cella D, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107:167\u2013180. https:\/\/doi.org\/10.1007\/s10549-007-9548-1","journal-title":"Breast Cancer Res Treat"},{"key":"9258_CR4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","volume":"154","author":"A Freites-Martinez","year":"2018","unstructured":"Freites-Martinez A, Shapiro J, Chan D et al (2018) Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol 154:670\u2013675. https:\/\/doi.org\/10.1001\/jamadermatol.2018.0454","journal-title":"JAMA Dermatol"},{"key":"9258_CR5","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","volume":"18","author":"V Saggar","year":"2013","unstructured":"Saggar V, Wu S, Dickler MN et al (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18:1126\u20131134. https:\/\/doi.org\/10.1634\/theoncologist.2013-0193","journal-title":"Oncologist"},{"key":"9258_CR6","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1200\/JOP.2012.000543","volume":"8","author":"EJA Bowles","year":"2012","unstructured":"Bowles EJA, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8:e149\u2013e157. https:\/\/doi.org\/10.1200\/JOP.2012.000543","journal-title":"J Oncol Pract"},{"key":"9258_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10549-018-4996-3","volume":"174","author":"RN Rozner","year":"2019","unstructured":"Rozner RN, Freites-Martinez A, Shapiro J et al (2019) Safety of 5\u03b1-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Breast Cancer Res Treat 174:15\u201326. https:\/\/doi.org\/10.1007\/s10549-018-4996-3","journal-title":"Breast Cancer Res Treat"},{"key":"9258_CR8","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.3390\/curroncol30040275","volume":"30","author":"TC Wikramanayake","year":"2023","unstructured":"Wikramanayake TC, Haberland NI, Akhundlu A et al (2023) Prevention and treatment of chemotherapy-induced alopecia: what is available and what is coming? Curr Oncol 30:3609\u20133626. https:\/\/doi.org\/10.3390\/curroncol30040275","journal-title":"Curr Oncol"},{"key":"9258_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamadermatol.2022.4867","volume":"159","author":"L Drake","year":"2023","unstructured":"Drake L, Reyes-Hadsall S, Martinez J et al (2023) Evaluation of the safety and effectiveness of nutritional supplements for treating hair loss: a systematic review. JAMA Dermatol 159:79\u201386. https:\/\/doi.org\/10.1001\/jamadermatol.2022.4867","journal-title":"JAMA Dermatol"},{"key":"9258_CR10","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.3390\/nu12113537","volume":"12","author":"G Dell'Acqua","year":"2020","unstructured":"Dell\u2019Acqua G, Richards A, Thornton MJ (2020) The potential role of nutraceuticals as an adjuvant in breast cancer patients to prevent hair loss induced by endocrine therapy. Nutrients 12:3537. https:\/\/doi.org\/10.3390\/nu12113537","journal-title":"Nutrients"},{"key":"9258_CR11","unstructured":"National Comprehensive Cancer Network (2024) National Comprehensive Cancer Network (NCCN) Guidelines for Breast Cancer, Version 5.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 29 October 2024"},{"key":"9258_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/0284186X.2020.1738547","volume":"59","author":"D Eiger","year":"2020","unstructured":"Eiger D, Wagner M, Pond\u00e9 NF et al (2020) The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). Acta Oncol 59:723\u2013725. https:\/\/doi.org\/10.1080\/0284186X.2020.1738547","journal-title":"Acta Oncol"},{"key":"9258_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/1523-1747.ep12335779","volume":"109","author":"ME Sawaya","year":"1997","unstructured":"Sawaya ME, Price VH (1997) Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 109:296\u2013300. https:\/\/doi.org\/10.1111\/1523-1747.ep12335779","journal-title":"J Invest Dermatol"},{"key":"9258_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s00520-023-07634-5","volume":"31","author":"L Rose","year":"2023","unstructured":"Rose L, Lustberg M, Ruddy KJ et al (2023) Hair loss during and after breast cancer therapy. Support Care Cancer 31:186. https:\/\/doi.org\/10.1007\/s00520-023-07634-5","journal-title":"Support Care Cancer"},{"key":"9258_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1634\/theoncologist.2017-0263","volume":"23","author":"CJ Dunnill","year":"2018","unstructured":"Dunnill CJ, Al-Tameemi W, Collett A et al (2018) A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention. Oncologist 23:84\u201396. https:\/\/doi.org\/10.1634\/theoncologist.2017-0263","journal-title":"Oncologist"},{"key":"9258_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3109\/09546634.2013.813011","volume":"25","author":"AK Gupta","year":"2014","unstructured":"Gupta AK, Charrette, (2014) The efficacy and safety of 5\u03b1-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat 25:156\u2013161. https:\/\/doi.org\/10.3109\/09546634.2013.813011","journal-title":"J Dermatolog Treat"},{"key":"9258_CR17","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-016-0629-5","volume":"76","author":"Y Kelly","year":"2016","unstructured":"Kelly Y, Blanco A, Tosti A (2016) Androgenetic alopecia: an update of treatment options. Drugs 76:1349\u20131364. https:\/\/doi.org\/10.1007\/s40265-016-0629-5","journal-title":"Drugs"},{"key":"9258_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1468-3083.2010.03758.x","volume":"25","author":"JH Yeon","year":"2011","unstructured":"Yeon JH, Jung JY, Choi JW et al (2011) 5 mg\/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol 25:211\u2013214. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03758.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9258_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4103\/0974-7753.114709","volume":"5","author":"R Oliveira-Soares","year":"2013","unstructured":"Oliveira-Soares R, Silva E, JM, Correia MP, et al (2013) Finasteride 5 mg\/day treatment of patterned hair loss in normo-androgenetic postmenopausal women. Int J Trichology 5:22\u201325. https:\/\/doi.org\/10.4103\/0974-7753.114709","journal-title":"Int J Trichology"},{"key":"9258_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000079890","volume":"209","author":"RM Tr\u00fceb","year":"2004","unstructured":"Tr\u00fceb RM (2004) Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 209:202\u2013207. https:\/\/doi.org\/10.1159\/000079890","journal-title":"Dermatology"},{"key":"9258_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jdcr.2023.02.021","volume":"35","author":"C Dubin","year":"2023","unstructured":"Dubin C, Lamb A (2023) Hair regrowth in endocrine therapy alopecia with dutasteride treatment in woman with estrogen positive breast cancer. JAAD Case Rep 35:5\u20137. https:\/\/doi.org\/10.1016\/j.jdcr.2023.02.021","journal-title":"JAAD Case Rep"},{"key":"9258_CR22","doi-asserted-by":"publisher","first-page":"490","DOI":"10.37349\/etat.2021.00059","volume":"2","author":"A Rossi","year":"2021","unstructured":"Rossi A, Caro G, Magri F et al (2021) Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer. Explor Target Antitumor Ther 2:490\u2013495. https:\/\/doi.org\/10.37349\/etat.2021.00059","journal-title":"Explor Target Antitumor Ther"},{"key":"9258_CR23","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s10552-014-0455-6","volume":"25","author":"RG Duijnhoven","year":"2014","unstructured":"Duijnhoven RG, Straus SM, Souverein PC et al (2014) Long-term use of 5\u03b1-reductase inhibitors and the risk of male breast cancer. Cancer Causes Control 25:1577\u20131582. https:\/\/doi.org\/10.1007\/s10552-014-0455-6","journal-title":"Cancer Causes Control"},{"key":"9258_CR24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.juro.2013.04.132","volume":"190","author":"ST Bird","year":"2013","unstructured":"Bird ST, Brophy JM, Hartzema AG et al (2013) Male breast cancer and 5\u03b1-reductase inhibitors finasteride and dutasteride. J Urol 190:1811\u20131814. https:\/\/doi.org\/10.1016\/j.juro.2013.04.132","journal-title":"J Urol"},{"key":"9258_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/cam4.1273","volume":"7","author":"M Meijer","year":"2018","unstructured":"Meijer M, Thygesen LC, Green A et al (2018) Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries. Cancer Med 7:254\u2013260. https:\/\/doi.org\/10.1002\/cam4.1273","journal-title":"Cancer Med"},{"key":"9258_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/jamadermatol.2016.5790","volume":"153","author":"EJ van Zuuren","year":"2017","unstructured":"van Zuuren EJ, Fedorowicz Z (2017) Interventions for female pattern hair loss. JAMA Dermatol 153:329\u2013330. https:\/\/doi.org\/10.1001\/jamadermatol.2016.5790","journal-title":"JAMA Dermatol"},{"key":"9258_CR27","doi-asserted-by":"publisher","first-page":"e43559","DOI":"10.7759\/cureus.43559","volume":"15","author":"M Aleissa","year":"2023","unstructured":"Aleissa M (2023) The efficacy and safety of oral spironolactone in the treatment of female pattern hair loss: a systematic review and meta-analysis. Cureus 15:e43559. https:\/\/doi.org\/10.7759\/cureus.43559","journal-title":"Cureus"},{"key":"9258_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2021.07.048","volume":"86","author":"JF James","year":"2022","unstructured":"James JF, Jamerson TA, Aguh C (2022) Efficacy and safety profile of oral spironolactone use for androgenic alopecia: a systematic review. J Am Acad Dermatol 86:425\u2013429. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.048","journal-title":"J Am Acad Dermatol"},{"key":"9258_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jaad.2020.03.087","volume":"83","author":"LJ Burns","year":"2020","unstructured":"Burns LJ, Souza BD, Flynn E et al (2020) Spironolactone for treatment of female pattern hair loss. J Am Acad Dermatol 83:276\u2013278. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.087","journal-title":"J Am Acad Dermatol"},{"key":"9258_CR30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1365-2133.2005.06218.x","volume":"152","author":"R Sinclair","year":"2005","unstructured":"Sinclair R, Wewerinke M, Jolley D (2005) Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 152:466\u2013473. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06218.x","journal-title":"Br J Dermatol"},{"key":"9258_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2147\/CCID.S398950","volume":"16","author":"C Wang","year":"2023","unstructured":"Wang C, Du Y, Bi L et al (2023) The efficacy and safety of oral and topical spironolactone in androgenetic alopecia treatment: a systematic review. Clin Cosmet Investig Dermatol 16:603\u2013612. https:\/\/doi.org\/10.2147\/CCID.S398950","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"9258_CR32","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaad.2020.05.081","volume":"83","author":"C Wei","year":"2020","unstructured":"Wei C, Bovonratwet P, Gu A et al (2020) Spironolactone use does not increase the risk of female breast cancer recurrence: a retrospective analysis. J Am Acad Dermatol 83:1021\u20131027. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.081","journal-title":"J Am Acad Dermatol"},{"key":"9258_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamadermatol.2021.5866","volume":"158","author":"K Bommareddy","year":"2022","unstructured":"Bommareddy K, Hamade H, Lopez-Olivo MA et al (2022) Association of spironolactone use with risk of cancer: a systematic review and meta-analysis. JAMA Dermatol 158:275\u2013282. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5866","journal-title":"JAMA Dermatol"},{"key":"9258_CR34","doi-asserted-by":"publisher","first-page":"e083","DOI":"10.1097\/JW9.0000000000000083","volume":"9","author":"MG Buontempo","year":"2023","unstructured":"Buontempo MG, Alhanshali L, Shapiro J et al (2023) Exploring the historical stigma of spironolactone use in breast cancer survivors with alopecia. Int J Womens Dermatol 9:e083. https:\/\/doi.org\/10.1097\/JW9.0000000000000083","journal-title":"Int J Womens Dermatol"},{"key":"9258_CR35","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.2147\/DDDT.S214907","volume":"13","author":"P Suchonwanit","year":"2019","unstructured":"Suchonwanit P, Thammarucha S, Leerunyakul K (2019) Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther 13:2777\u20132786. https:\/\/doi.org\/10.2147\/DDDT.S214907","journal-title":"Drug Des Devel Ther"},{"key":"9258_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/dth.12390","volume":"29","author":"A Rossi","year":"2016","unstructured":"Rossi A, Anzalone A, Fortuna MC et al (2016) Multi-therapies in androgenetic alopecia: review and clinical experiences. Dermatol Ther 29:424\u2013432. https:\/\/doi.org\/10.1111\/dth.12390","journal-title":"Dermatol Ther"},{"key":"9258_CR37","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1080\/09546634.2021.1945527","volume":"33","author":"AK Gupta","year":"2022","unstructured":"Gupta AK, Talukder M, Venkataraman M et al (2022) Minoxidil: a comprehensive review. J Dermatol Treat 33:1896\u20131906. https:\/\/doi.org\/10.1080\/09546634.2021.1945527","journal-title":"J Dermatol Treat"},{"key":"9258_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00520-023-08160-0","volume":"31","author":"A Minta","year":"2023","unstructured":"Minta A, Rose L, Park C et al (2023) Retrospective cohort study of CDK4\/6-inhibitor-induced alopecia in breast cancer patients. Support Care Cancer 31:717. https:\/\/doi.org\/10.1007\/s00520-023-08160-0","journal-title":"Support Care Cancer"},{"key":"9258_CR39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-024-07440-5","volume":"208","author":"AMS Kuo","year":"2024","unstructured":"Kuo AMS, Reingold RE, Ketosugbo KF et al (2024) Oral minoxidil for late alopecia in cancer survivors. Breast Cancer Res Treat 208:491\u2013499. https:\/\/doi.org\/10.1007\/s10549-024-07440-5","journal-title":"Breast Cancer Res Treat"},{"key":"9258_CR40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaad.2020.06.1009","volume":"84","author":"M Randolph","year":"2021","unstructured":"Randolph M, Tosti A (2021) Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol 84:737\u2013746. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.1009","journal-title":"J Am Acad Dermatol"},{"key":"9258_CR41","doi-asserted-by":"publisher","first-page":"729","DOI":"10.4103\/idoj.idoj_246_22","volume":"13","author":"HA Ram\u00edrez-Mar\u00edn","year":"2022","unstructured":"Ram\u00edrez-Mar\u00edn HA, Tosti A (2022) Role of oral minoxidil in patterned hair loss. Indian Dermatol Online J 13:729\u2013733. https:\/\/doi.org\/10.4103\/idoj.idoj_246_22","journal-title":"Indian Dermatol Online J"},{"key":"9258_CR42","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jaad.2022.12.005","volume":"88","author":"J Kang","year":"2023","unstructured":"Kang J, Lee JW, Kwon O (2023) Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: a retrospective cohort study. J Am Acad Dermatol 88:1170\u20131173. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.005","journal-title":"J Am Acad Dermatol"},{"key":"9258_CR43","unstructured":"Patel P, Nessel TA, Kumar D D (2024) Minoxidil. In: StatPearls (Internet), Updated 9 June 2024. Treasure Island, Florida. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482378\/. Accessed 27 May 2024."},{"key":"9258_CR44","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.1111\/jocd.15138","volume":"21","author":"EJ Klein","year":"2022","unstructured":"Klein EJ, Karim M, Shapiro J et al (2022) Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia: a retrospective chart review. J Cosmet Dermatol 21:6473\u20136475. https:\/\/doi.org\/10.1111\/jocd.15138","journal-title":"J Cosmet Dermatol"},{"key":"9258_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000343174","volume":"26","author":"A Herman","year":"2012","unstructured":"Herman A, Herman AP (2012) Caffeine\u2019s mechanisms of action and its cosmetic use. Skin Pharmacol Physiol 26:8\u201314. https:\/\/doi.org\/10.1159\/000343174","journal-title":"Skin Pharmacol Physiol"},{"key":"9258_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000508228","volume":"33","author":"JM V\u00f6lker","year":"2020","unstructured":"V\u00f6lker JM, Koch N, Becker M et al (2020) Caffeine and its pharmacological benefits in the management of androgenetic alopecia: a review. Skin Pharmacol Physiol 33:93\u2013109. https:\/\/doi.org\/10.1159\/000508228","journal-title":"Skin Pharmacol Physiol"},{"key":"9258_CR47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000492035","volume":"5","author":"AM Hosking","year":"2019","unstructured":"Hosking AM, Juhasz M, Atanaskova Mesinkovska N (2019) Complementary and alternative treatments for alopecia: a comprehensive review. Skin Appendage Disord 5:72\u201389. https:\/\/doi.org\/10.1159\/000492035","journal-title":"Skin Appendage Disord"},{"key":"9258_CR48","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000481141","volume":"30","author":"R Dhurat","year":"2018","unstructured":"Dhurat R, Chitallia J, May TW et al (2018) An open-label randomized multicenter study assessing the noninferiority of a caffeine-based topical liquid 0.2% versus minoxidil 5% solution in male androgenetic alopecia. Skin Pharmacol Physiol 30:298\u2013305. https:\/\/doi.org\/10.1159\/000481141","journal-title":"Skin Pharmacol Physiol"},{"key":"9258_CR49","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/jn\/nxaa040","volume":"150","author":"M Du","year":"2020","unstructured":"Du M, Luo H, Blumberg JB et al (2020) Dietary supplement use among adult cancer survivors in the United States. J Nutr 150:1499\u20131508. https:\/\/doi.org\/10.1093\/jn\/nxaa040","journal-title":"J Nutr"},{"key":"9258_CR50","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1200\/JCO.2007.13.5905","volume":"26","author":"CM Velicer","year":"2008","unstructured":"Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol Off J Am Soc Clin Oncol 26:665\u2013673. https:\/\/doi.org\/10.1200\/JCO.2007.13.5905","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"9258_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s13555-018-0278-6","volume":"9","author":"HM Almohanna","year":"2018","unstructured":"Almohanna HM, Ahmed AA, Tsatalis JP et al (2018) The role of vitamins and minerals in hair loss: a review. Dermatol Ther 9:51\u201370. https:\/\/doi.org\/10.1007\/s13555-018-0278-6","journal-title":"Dermatol Ther"},{"key":"9258_CR52","unstructured":"American Academy of Dermatology Association. Hair Loss: Diagnosis and Treatment. https:\/\/www.aad.org\/public\/diseases\/hair-loss\/treatment\/diagnosis-treat. Accessed 29 October 2024"},{"key":"9258_CR53","doi-asserted-by":"publisher","first-page":"e231337","DOI":"10.1136\/bcr-2019-231337","volume":"13","author":"MS Lundin","year":"2020","unstructured":"Lundin MS, Alratroot A, Abu Rous F et al (2020) When thyroid labs do not add up, physicians should ask patients about biotin supplements. BMJ Case Rep 13:e231337. https:\/\/doi.org\/10.1136\/bcr-2019-231337","journal-title":"BMJ Case Rep"},{"key":"9258_CR54","first-page":"558","volume":"17","author":"G Ablon","year":"2018","unstructured":"Ablon G, Kogan S (2018) A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol JDD 17:558\u2013565","journal-title":"J Drugs Dermatol JDD"},{"key":"9258_CR55","unstructured":"VEGAMOUR (2024) GRO Hair Serum. https:\/\/vegamour.com\/products\/gro-hair-serum. Accessed 27 May 2024"},{"key":"9258_CR56","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4103\/0974-7753.171573","volume":"7","author":"RL Rizer","year":"2015","unstructured":"Rizer RL, Stephens TJ, Herndon JH et al (2015) A marine protein-based dietary supplement for subclinical hair thinning\/loss: results of a multisite, double-blind, placebo-controlled clinical trial. Int J Trichology 7:156\u2013166. https:\/\/doi.org\/10.4103\/0974-7753.171573","journal-title":"Int J Trichology"},{"key":"9258_CR57","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s13555-023-00974-4","volume":"13","author":"M Escamilla-Cruz","year":"2023","unstructured":"Escamilla-Cruz M, Maga\u00f1a M, Escand\u00f3n-Perez S et al (2023) Use of 5-alpha reductase inhibitors in dermatology: a narrative review. Dermatol Ther 13:1721\u20131731. https:\/\/doi.org\/10.1007\/s13555-023-00974-4","journal-title":"Dermatol Ther"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09258-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09258-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09258-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T01:27:42Z","timestamp":1742002062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09258-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["9258"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09258-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"23 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}